Logo

Adial Pharmaceuticals, Inc.

ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain… read more

Healthcare

Biotechnology

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.34

Price

+2.81%

$0.01

Market Cap

$7.510m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$560

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$8.450m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.01

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$5.591m

$6.802m

Assets

$1.211m

Liabilities

-

Debt
Debt to Assets

0.00%

-

Debt to EBITDA
Free Cash Flow

-$6.483m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases